Hot Features
プレミアム
Channel Therapeutics Corporation (CHRO)
AMEX
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. 詳細を表示
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0691 | -10.0232085872 | 0.6894 | 0.6894 | 0.5633 | 210299 | 0.59961457 | CS |
| 4 | 0.0013 | 0.210016155089 | 0.619 | 0.88 | 0.5513 | 163856 | 0.6990816 | CS |
| 12 | -0.3496 | -36.0449530879 | 0.9699 | 1.04 | 0.45 | 161435 | 0.73252942 | CS |
| 26 | -0.7897 | -56.0070921986 | 1.41 | 1.75 | 0.45 | 99675 | 0.80642223 | CS |
| 52 | -5.3797 | -89.6616666667 | 6 | 6 | 0.45 | 69129 | 1.06548021 | CS |
| 156 | -5.3797 | -89.6616666667 | 6 | 6 | 0.45 | 69129 | 1.06548021 | CS |
| 260 | -5.3797 | -89.6616666667 | 6 | 6 | 0.45 | 69129 | 1.06548021 | CS |
| 銘柄コード | 株価 | 出来高 |
|---|---|---|
| SPYSPDR S&P 500 | US$ 591.15 (0.86%) | 122.49M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 6.1628 (-3.25%) | 114.87M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 27.30 (3.80%) | 108.08M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2.435 (7.27%) | 94.23M |
| KULRKULR Technology Group Inc | US$ 2.885 (28.79%) | 75.72M |
shajandr
3分前
jeunke22
18分前
LoveThemStocks
21分前
TurboMountain96
28分前
SilkRoad
30分前
SilkRoad
33分前
happyglass
36分前
jeunke22
37分前
Sheepdog
40分前
knrorrel
40分前
ElectricMountain53
40分前
knrorrel
41分前
knrorrel
48分前
knrorrel
53分前
CanItBThisEZ2Make
59分前
gimmee greenbacks
60分前
Not likely
60分前
coccyx
1時間前
sylvia07
1時間前
rx7171
1時間前
powerbattles
1時間前
happyglass
1時間前
jeunke22
1時間前
jimmy051357
1時間前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
